patents as topic


Summary: Works about exclusive legal rights or privileges applied to inventions, plants, etc.

Top Publications

  1. Van Woert M. Orphan Drug Act. Prog Clin Biol Res. 1985;197:7-9 pubmed
  2. Ratner M. Pfizer stakes a claim in plant cell-made biopharmaceuticals. Nat Biotechnol. 2010;28:107-8 pubmed publisher
  3. Jannuzzi A, Vasconcellos A. [How much does the backlog on drug patents cost for health in Brazil?]. Cad Saude Publica. 2017;33:e00206516 pubmed publisher
  4. Hussain H, Green I. A patent review of the therapeutic potential of isoflavones (2012-2016). Expert Opin Ther Pat. 2017;27:1135-1146 pubmed publisher
    ..However, the absence of SAR studies and in vivo data restricted the rational design of more potent isoflavone analogs and we believe that in order to get lead compounds, there needs to be a greater focus on SAR and in vivo studies. ..
  5. Sun H, Zhu J, Lin H, Gu K, Feng F. Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016). Expert Opin Ther Pat. 2017;27:763-785 pubmed publisher
    ..Finally, per the mechanism of the Nrf2 modulator, compounds with the most active Nrf2 inductivity maybe not the best choice for the design of an ideal chemopreventive agent. ..
  6. Kesselheim A, Sinha M, Avorn J. Determinants of Market Exclusivity for Prescription Drugs in the United States. JAMA Intern Med. 2017;177:1658-1664 pubmed publisher
    ..The goal of policy in this area should be to ensure that drug market exclusivity periods provide for fair return on investment but do not indefinitely block availability of lower-cost generic drugs. ..
  7. He G, Di X, Sun X, Yan J, Zhang S. Analysis of radio-sensitization patents in China from 2006 to 2015. Expert Opin Ther Pat. 2017;27:1159-1172 pubmed publisher
    ..To find effective ways to improve the sensitivity of tumor cells to radiation therapy has become a focus in scientific research and clinical treatment. So radiation sensitivity has been proposed and widely studied. ..
  8. Pashkov V, Harkusha A. 3-D bioprinting law regulation perspectives. Wiad Lek. 2017;70:480-482 pubmed
    ..The main instruments for this must be balanced regulation of intellectual property (IP) rights, regulation of access and distribution, premarket restrictions, control mechanism etc. ..
  9. McKernan K, Spangler J, Helbert Y, Zhang L, Tadigotla V. DREAMing of a patent-free human genome for clinical sequencing. Nat Biotechnol. 2013;31:884-7 pubmed publisher

More Information


  1. Hussain H, Green I, Ali I, Khan I, Ali Z, Al Sadi A, et al. Ursolic acid derivatives for pharmaceutical use: a patent review (2012-2016). Expert Opin Ther Pat. 2017;27:1061-1072 pubmed publisher
    ..Most importantly, UA has the potential to conjugate with other anticancer drugs or be transformed into its halo derivatives since this will greatly facilitate scientists to get lead compounds in cancer drug discovery. ..
  2. Boss C, Roch C. Orexin research: patent news from 2016. Expert Opin Ther Pat. 2017;27:1123-1133 pubmed publisher
    ..It might also influence the efforts in the identification of orexin receptor agonists. Being potential treatments for narcolepsy with cataplexy. ..
  3. Claudel M, Massaro E, Santi P, Murray F, Ratti C. An exploration of collaborative scientific production at MIT through spatial organization and institutional affiliation. PLoS ONE. 2017;12:e0179334 pubmed publisher
    ..These insights contribute an architectural dimension to the field of scientometrics, and take a first step toward empirical space-planning policy that supports collaboration within institutions. ..
  4. Oliveira M, Guimarães A, Araújo A, Quintans Júnior L, Quintans J. New drugs or alternative therapy to blurring the symptoms of fibromyalgia-a patent review. Expert Opin Ther Pat. 2017;27:1147-1157 pubmed publisher
  5. Graham T. Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review. Expert Opin Ther Pat. 2017;27:1077-1088 pubmed publisher
    ..Additional fundamental research into the signaling pathways is likely required before the true therapeutic potential of PrCP inhibition will be realized. ..
  6. Ledford H. Broad Institute wins bitter battle over CRISPR patents. Nature. 2017;542:401 pubmed publisher
  7. Mucke H. Focus, medicinal chemistry, informatics: towards the pharmaceutical patentome. Pharm Pat Anal. 2012;1:229-31 pubmed publisher
  8. Limb M. Roche's decision to drop Herceptin patent in India opens way for generics. BMJ. 2013;347:f5197 pubmed publisher
  9. Grushkin D. Threat to global GM soybean access as patent nears expiry. Nat Biotechnol. 2013;31:10-1 pubmed publisher
  10. Git A. Research tools: A recipe for disaster. Nature. 2012;484:439-40 pubmed publisher
  11. Basnet S, Magee C. Artifact interactions retard technological improvement: An empirical study. PLoS ONE. 2017;12:e0179596 pubmed publisher
    ..56 with a p-value of 0.002. The results agree with model predictions, and provide, for the first time, empirical evidence that artifact interactions have a retarding effect on improvement rates of technological domains. ..
  12. . The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439-42 pubmed publisher
  13. Di Martino R, Bisi A, Rampa A, Gobbi S, Belluti F. Recent progress on curcumin-based therapeutics: a patent review (2012-2016). Part II: curcumin derivatives in cancer and neurodegeneration. Expert Opin Ther Pat. 2017;27:953-965 pubmed publisher
  14. Pradeep P, Kumar P, Choonara Y, Pillay V. Targeted nanotechnologies for cancer intervention: a patent review (2010-2016). Expert Opin Ther Pat. 2017;27:1005-1019 pubmed publisher
  15. Belda I, Penas G, Alonso A, Marquina D, Navascués E, Santos A. Biotech patents and science policy: the Spanish experience. Nat Biotechnol. 2014;32:59-61 pubmed publisher
  16. Mahapatra D, Asati V, Bharti S. MEK inhibitors in oncology: a patent review (2015-Present). Expert Opin Ther Pat. 2017;27:887-906 pubmed publisher
    ..The combination and/or multi-targeted kinase/mutant gene inhibitors may be a therapeutic option for the personalized cancer treatment of patients with relapsed or refractory multiple myeloma. ..
  17. Agarwal S, Agarwal H, Zaware N. Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells US2015011543 (a1): a patent evaluation. Expert Opin Ther Pat. 2017;27:1177-1181 pubmed publisher
    ..The numerous literature reports and biological data indicates that these pyrimido[4,5-b]indole derivatives are promising candidates for the development of potential therapies for hematopoietic ailments. ..
  18. Hughes D, Ferner R. New drugs for old: disinvestment and NICE. BMJ. 2010;340:c572 pubmed publisher
  19. Kalinin D, Holl R. LpxC inhibitors: a patent review (2010-2016). Expert Opin Ther Pat. 2017;27:1227-1250 pubmed publisher
    ..The lack of clinical candidates might be related with undesired effects caused by the common structural elements of the LpxC inhibitors. ..
  20. Scheinberg M, Castaneda Hernandez G. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice. Arthritis Res Ther. 2014;16:501 pubmed publisher
    ..This article comments on various aspects surrounding the use of such biocopies in clinical rheumatology. ..
  21. Pardey P, Koo B, Drew J, Horwich J, Nottenburg C. The evolving landscape of plant varietal rights in the United States, 1930-2008. Nat Biotechnol. 2013;31:25-9 pubmed publisher
  22. Cheng X, Gao P, Sun L, Tian Y, Zhan P, Liu X. Identification of spirocyclic or phosphate substituted quinolizine derivatives as novel HIV-1 integrase inhibitors: a patent evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1. Expert Opin Ther Pat. 2017;27:1277-1286 pubmed publisher
  23. Cohen J. The Birth of CRISPR Inc. Science. 2017;355:680-684 pubmed publisher
  24. Bergeaud A, Potiron Y, Raimbault J. Classifying patents based on their semantic content. PLoS ONE. 2017;12:e0176310 pubmed publisher
    ..Moreover, we document that both approaches have highly different topological measures and strong statistical evidence that they feature a different model. This suggests that our method is a useful tool to extract endogenous information. ..
  25. Nguyen T, Fruit C, Herault Y, Meijer L, Besson T. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. Expert Opin Ther Pat. 2017;27:1183-1199 pubmed publisher
  26. Amusan L. POLITICS OF BIOPIRACY: AN ADVENTURE INTO HOODIA/XHOBA PATENTING IN SOUTHERN AFRICA. Afr J Tradit Complement Altern Med. 2017;14:103-109 pubmed publisher
  27. t Hoen E. Assuring access to quality antiretroviral medicines: the WHO Prequalification of Medicines Program and access to HIV treatment. Cad Saude Publica. 2014;30:908-9 pubmed
  28. Pasche E, Gobeill J, Kreim O, Oezdemir Zaech F, Vachon T, Lovis C, et al. Development and tuning of an original search engine for patent libraries in medicinal chemistry. BMC Bioinformatics. 2014;15 Suppl 1:S15 pubmed publisher
    ..We conclude that different search tasks demand different information retrieval engines' settings in order to yield optimal end-user retrieval. ..
  29. Greene J, Kesselheim A. Why do the same drugs look different? Pills, trade dress, and public health. N Engl J Med. 2011;365:83-9 pubmed publisher
  30. Frlan R, Gobec S. Evaluation of US 2016/0115161 A1: isoindoline compounds and methods of their use. Expert Opin Ther Pat. 2017;27:637-641 pubmed publisher
    ..Results of biological tests, which are superior over those of presently used IMIDs lenalidomide and pomalidomide, make these compounds viable leads for future development of new anticancer drugs against blood and solid cancers. ..
  31. Stazi G, Zwergel C, Mai A, Valente S. EZH2 inhibitors: a patent review (2014-2016). Expert Opin Ther Pat. 2017;27:797-813 pubmed publisher
    ..Several issues are still to be settled, such as drug resistance and the importance of selectivity over EZH1 or somatic EZH2 mutants. ..
  32. McGuire L. Genome editing: Broad Institute keeps CRISPR tools open. Nature. 2016;534:37 pubmed publisher
  33. Kharkar P. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017;27:753-761 pubmed publisher
    ..Drug repurposing can be attempted to discover newer anti-CSC drugs quickly. ..
  34. Levy S. Our shared code: the Myriad decision and the future of genetic research. Environ Health Perspect. 2013;121:A250-3 pubmed publisher
  35. Hameed A, Al Rashida M, Alharthy R, Uroos M, Mughal E, Ali S, et al. Small molecules as activators in medicinal chemistry (2000-2016). Expert Opin Ther Pat. 2017;27:1089-1110 pubmed publisher
    ..However only a few enzyme activators as drugs have made it to the market. Disorders characterized by supressed enzyme activity can be treated by enhancing the activity of a specific enzyme. ..
  36. Diependaele L, Cockbain J, Sterckx S. Raising the Barriers to Access to Medicines in the Developing World - The Relentless Push for Data Exclusivity. Dev World Bioeth. 2017;17:11-21 pubmed publisher
  37. Luo J, Kesselheim A. Evolution of insulin patents and market exclusivities in the USA. Lancet Diabetes Endocrinol. 2015;3:835-7 pubmed publisher
  38. Dyer O. Canadian hospital seeks to end patenting of human genes. BMJ. 2014;349:g6732 pubmed publisher
  39. Vokinger K, Kesselheim A, Avorn J, Sarpatwari A. Strategies That Delay Market Entry of Generic Drugs. JAMA Intern Med. 2017;177:1665-1669 pubmed publisher
    ..Finally, the FDA can provide earlier guidance on bioequivalence determinations for complex generic products and adopt the presumption that late-filed citizen petitions should be summarily rejected...
  40. Peng F, Liu D, Zhang Q, Xu Y, Shi L. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Expert Opin Ther Pat. 2017;27:987-1004 pubmed publisher
    ..Therefore, the development of multi-targeted tyrosine kinase inhibitors and the strategy of using these agents in conjunction with other anti-cancer agents are recent interesting therapeutic approaches that could give promising results. ..
  41. Hussain H, Green I. A patent review of two fruitful decades (1997-2016) of Isocoumarin research. Expert Opin Ther Pat. 2017;27:1267-1275 pubmed publisher
    ..Moreover, in order to get lead compounds, scientists should focus on the synthesis of halo and functionalized heterocyclic ring containing derivatives of isocoumarins as more potent drugs. ..
  42. Olle B. Medicines from microbiota. Nat Biotechnol. 2013;31:309-15 pubmed publisher
  43. Frampton S. Patents, priority disputes and the value of credit: towards a history (and pre-history) of intellectual property in medicine. Med Hist. 2011;55:319-24 pubmed
  44. Yang Y, Yu T, Jiang S, Zhang Y, Li M, Tang N, et al. miRNAs as potential therapeutic targets and diagnostic biomarkers for cardiovascular disease with a particular focus on WO2010091204. Expert Opin Ther Pat. 2017;27:1021-1029 pubmed publisher
    ..Overall, targeting miRNAs is definitely a promising strategy to be investigated for diagnosis and treatment of CVDs in future, however, the delivery system and off-targets effects are still a difficult challenge need to be elucidated. ..
  45. Hussain H, Green I. Lapachol and lapachone analogs: a journey of two decades of patent research(1997-2016). Expert Opin Ther Pat. 2017;27:1111-1121 pubmed publisher
    ..It is our opinion that in order to get lead compounds, there needs to be a greater focus on the elucidation of the precise mechanism of action of these compounds including SAR and in vivo studies...
  46. Albers S, Berklund A, Graff G. The rise and fall of innovation in biofuels. Nat Biotechnol. 2016;34:814-21 pubmed publisher
  47. Melese T, Lin S, Chang J, Cohen N. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med. 2009;15:502-7 pubmed publisher
  48. Psarra A, Nikolaou A, Kokotou M, Limnios D, Kokotos G. Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review. Expert Opin Ther Pat. 2017;27:1047-1059 pubmed publisher
    ..More preclinical and clinical studies on mPGES-1 inhibitors are needed to realize if indeed they may become novel agents for the treatment of inflammation and cancer. ..
  49. Nosengo N. Can you teach old drugs new tricks?. Nature. 2016;534:314-6 pubmed publisher
  50. Detsi A, Kontogiorgis C, Hadjipavlou Litina D. Coumarin derivatives: an updated patent review (2015-2016). Expert Opin Ther Pat. 2017;27:1201-1226 pubmed publisher
    ..Their clinical evaluation will be critical to assess therapeutic utility. The compounds for which the mechanism of action is well defined can serve as lead compounds for the design of new more potent molecules. ..
  51. Blagosklonny M. Damage-induced aging and perpetual motion. Cell Cycle. 2013;12:2709-10 pubmed publisher
  52. Miller A. Feds must step up and restrict generic oxycodone, Ontario says. CMAJ. 2012;184:E893-4 pubmed publisher
  53. Dolgin E. Business: The billion-dollar biotech. Nature. 2015;522:26-8 pubmed publisher